Meeting
2014 ASCO Annual Meeting
PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months.
Authors
Helena Margaret Earl
Department of Oncology, NIHR Cambridge Biomedical Research Centre and Cambridge Breast Cancer Research Unit, University of Cambridge, Cambridge, United Kingdom
Helena Margaret Earl , David A. Cameron , David Miles , Andrew M. Wardley , Emma Ogburn , Anne-Laure Vallier , Shrushma Loi , Louise Hiller , Janet Dunn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
52968807
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS656)
DOI
10.1200/jco.2014.32.15_suppl.tps656
Abstract #
TPS656
Poster Bd #
118A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer—Six versus twelve months.
First Author: Helena Margaret Earl
Poster
2012 ASCO Annual Meeting
The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.
First Author: Helena Margaret Earl
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani
Poster
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
First Author: Naomi RM Schwartz